Related Experiment Video

Updated: May 20, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

Prospective treatment of age-related diseases by slowing down aging

Mikhail V Blagosklonny1

  • 1Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. blagosklonny@oncotarget.com

The American Journal of Pathology
|July 31, 2012
PubMed

Insights

Targeting the aging process could prevent numerous age-related diseases. The rapamycin pathway shows promise in slowing aging and extending healthy lifespan, offering a unified therapeutic approach.

Area of Science:

  • Gerontology and molecular biology
  • Cellular senescence mechanisms
  • Aging research

Background:

  • Aging is linked to numerous chronic diseases, including cardiovascular disease, cancer, and neurodegenerative disorders.
  • Current treatments for age-related diseases are often symptomatic and disease-specific.
  • A common underlying aging process suggests a potential for a unified therapeutic strategy.

Purpose of the Study:

  • To explore the possibility of slowing down the aging process.
  • To investigate the role of the target of rapamycin (TOR) signaling pathway in aging.
  • To evaluate rapamycin's therapeutic potential across various age-related diseases.

Main Methods:

  • Review of preclinical and clinical studies on rapamycin and aging.
  • Analysis of the involvement of the TOR pathway in cellular senescence.
  • Examination of rapamycin's effects on diverse age-related conditions.

Main Results:

  • The target of rapamycin signaling pathway is implicated in cellular senescence and organismal aging.
  • Rapamycin has demonstrated therapeutic effects in preclinical and clinical studies for multiple age-related diseases.
  • Inhibition of the aging process via rapamycin offers a potential explanation for its broad efficacy.

Conclusions:

  • Slowing aging itself may delay or treat a spectrum of age-related diseases.
  • The TOR pathway is a key target for interventions aimed at modulating the aging process.
  • Rapamycin represents a promising therapeutic agent for increasing healthy life span and longevity.

More Related Videos

Techniques to Induce and Quantify Cellular Senescence06:51

Techniques to Induce and Quantify Cellular Senescence

Published on: May 1, 2017

Related Concept Videos

Aging01:26

Aging

Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...